Research summary
Receptor-surface charge helps determine functional responses to tested DR5 agonist antibodies.
Study context
Surface charge and DR5 antibody response
Why do antibodies to the same death receptor differ in their functional response?
How it was studied
The investigators combined receptor-level analysis with antibody-response experiments in the cell and tumor systems reported in the paper.
Selected findings
- Perturbation and antibody studies connect positively charged DR5 residues to functional efficacy.
- The work helps distinguish receptor recognition from productive death signaling in the tested contexts.
Mechanistic preclinical evidence; no patient-benefit conclusion follows from the receptor mapping.
Read the full project analysis → · View publication figures →
Authors
Cite this work
Gururaj Shivange, Tanmoy Mondal, Evan Lyerly, Sanchita Bhatnagar, Charles N Landen, Shivani Reddy, Jonathan Kim, Britney Doan, Paula Riddle, Jogender Tushir-Singh (2021). A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. Cell reports, 109953. https://doi.org/10.1016/j.celrep.2021.109953